Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-5)

Sum=135

Publishing Process of This Article

Item

Count

Browse

Download

Sum=18

Apr 15, 2025 (publication date) through Mar 28, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103855
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103855

Table 1 Summary of treatment regimens for control and observation groups

Treatment group	Treatment regimen	Chemotherapy regimen	Immunotherapy option	Dosage and administration
Control group	Standard treatment	XELOX (Oxaliplatin + Capecitabine)		Trastuzumab (6 mg/kg IV) on Day 1 of each cycle
		SOX (Oxaliplatin + S-1)
		Cisplatin + taxane
Observation group	Combination of standard treatment + ICI	XELOX (Oxaliplatin + Capecitabine)	Pembrolizumab (2 mg/kg IV), Camrelizumab (200 mg IV), Sintilimab (200 mg IV)	Pembrolizumab: Day 1 of each cycle; Camrelizumab/Sintilimab: Day 1 of each cycle
		SOX (Oxaliplatin + S-1)		Same as above
		Cisplatin + Nab-Paclitaxel

Citation: Zhang SH, Li W, Chen XY, Nie LL. Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients. World J Gastrointest Oncol 2025; 17(4): 103855
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103855.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103855